Organon: Remeron best for stressed depressives

Published By Datamonitor

Oral contraceptives: the debate continues

Despite the results of this study, which should help boost the market for the triphasic drugs in the US, uncertainty about the safety of third generation products remains high throughout Europe. This is expected to continue throughout 2002, following new research into the drugs' cardiovascular side effects and some high profile litigation in the UK.

Published By Datamonitor

Oral contraceptives: a further blow for manufacturers

The link with increased risk of cardiovascular disease has dogged the contraceptive pill since the time of its launch. For manufacturers of newer combined oral contraceptives (COCs), already struggling to improve their image among European consumers, further reports emphasizing the risk of stroke can only be bad news.

Published By Datamonitor

Online gaming: Microsoft prepares to take on Sony

Published By Datamonitor

Online Forums To Boost Physician Brand Loyalty

As the competitive atmosphere within the pharmaceutical industry continues to heighten, and companies struggle to differentiate their brand among physicians, Datamonitor identifies the provision of online forums as one of the most effective and cost-efficient ways of building physician brand loyalty.

Published By Datamonitor

Novuspharma: lymphoma drug well positioned for success

Published By Datamonitor

Novuspharma: lending a hand to Micromet

Novuspharma has agreed to co-develop Micromet's MT201, the only fully human antibody in development that targets the Ep-CAM molecule. The companies plan to begin phase II trials for the drug, across a wide range of cancers. Novuspharma's expertise and experience in oncology will aid MT201's development, but the companies will also need an experienced marketing partner.

Published By Datamonitor

Novo Nordisk: high risk but big prize without Novartis

Novo Nordisk has lost its partner in the development of NN6622, a new insulin sensitizer for the treatment of type 2 diabetes. The company's decision to continue the development of this compound alone carries a high risk. However, in the unlikely event that it does launch, the rewards for Novo Nordisk would be extremely high.

Published By Datamonitor

Novo Nordisk/Dr Reddy's: cancer fears freeze diabetes drug

Novo Nordisk has suspended human trials of ragaglitazar, after discovering tumors in rodents that had been fed the experimental drug. The possible loss of ragaglitazar, which had been forecast peak annual sales of $1.78 billion, is Novo Nordisk's third setback this year. It also hits the drug's originator Dr Reddy's hard.

Published By Datamonitor

Novartis: Prexige proves a pain for Pharmacia

New trial results suggest that Novartis' 400mg Prexige is superior to 200mg Celebrex at providing pain relief for osteoarthritis patients. However, further studies will be needed to consider like-for-like tests and cardiovascular side effects. The results of these will be critical to Prexige's positioning in the extremely competitive pain relief market.

Published By Datamonitor